These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37235909)
1. "Paradoxical" p16 overexpression in cutaneous melanoma: Molecular and immunohistochemical analysis of a rare phenomenon with a focus on cell cycle regulatory molecules. Ricci C; Dika E; Corti B; Lambertini M; Ambrosi F; Cappilli S; Grillini M; Filippo GD; Franchini E; Maloberti T; Fiorentino M; Tallini G; Biase D Pathol Res Pract; 2023 Jul; 247():154564. PubMed ID: 37235909 [TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing revealing TP53 mutation as potential genetic driver in dermal deep-seated melanoma arising in giant congenital nevus in adult patients: A unique case report and review of the literature. Ricci C; Ambrosi F; Grillini M; Serra M; Melotti B; Gruppioni E; Altimari A; Fiorentino M; Dika E; Lambertini M; Corti B J Cutan Pathol; 2020 Dec; 47(12):1164-1169. PubMed ID: 32643812 [TBL] [Abstract][Full Text] [Related]
3. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. Yang G; Rajadurai A; Tsao H J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692 [TBL] [Abstract][Full Text] [Related]
5. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma. Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303 [TBL] [Abstract][Full Text] [Related]
6. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137 [TBL] [Abstract][Full Text] [Related]
7. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Burnworth B; Arendt S; Muffler S; Steinkraus V; Bröcker EB; Birek C; Hartschuh W; Jauch A; Boukamp P Eur J Cell Biol; 2007 Dec; 86(11-12):763-80. PubMed ID: 17198740 [TBL] [Abstract][Full Text] [Related]
8. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Jayasurya R; Sathyan KM; Lakshminarayanan K; Abraham T; Nalinakumari KR; Abraham EK; Nair MK; Kannan S Mod Pathol; 2005 Aug; 18(8):1056-66. PubMed ID: 15731778 [TBL] [Abstract][Full Text] [Related]
9. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736 [TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Edmunds SC; Kelsell DP; Hungerford JL; Cree IA Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501 [TBL] [Abstract][Full Text] [Related]
11. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. DeLeon TT; Almquist DR; Kipp BR; Langlais BT; Mangold A; Winters JL; Kosiorek HE; Joseph RW; Dronca RS; Block MS; McWilliams RR; Kottschade LA; Rumilla KM; Voss JS; Seetharam M; Sekulic A; Markovic SN; Bryce AH PLoS One; 2020; 15(3):e0230306. PubMed ID: 32196516 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma. Kanavaros P; Stefanaki K; Vlachonikolis J; Papalazarou D; Rontogianni D; Arvanitis D; Antonakopoulos G; Gorgoulis V; Bai M; Agnantis NJ Anticancer Res; 2000; 20(6B):4619-25. PubMed ID: 11205312 [TBL] [Abstract][Full Text] [Related]
14. Altered Rb, p16, and p53 expression is specific for porocarcinoma relative to poroma. Zahn J; Chan MP; Wang G; Patel RM; Andea AA; Bresler SC; Harms PW J Cutan Pathol; 2019 Sep; 46(9):659-664. PubMed ID: 31012122 [TBL] [Abstract][Full Text] [Related]
15. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. Wu MS; Shun CT; Sheu JC; Wang HP; Wang JT; Lee WJ; Chen CJ; Wang TH; Lin JT J Gastroenterol Hepatol; 1998 Mar; 13(3):305-10. PubMed ID: 9570245 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneous topographic profiles of kinetic and cell cycle regulator microsatellites in atypical (dysplastic) melanocytic nevi. Husain EA; Mein C; Pozo L; Blanes A; Diaz-Cano SJ Mod Pathol; 2011 Apr; 24(4):471-86. PubMed ID: 21336261 [TBL] [Abstract][Full Text] [Related]
19. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions. Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and clinical outcomes associated with TP53 and BRAF Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]